Prevention of chronic rhinosinusitis

Hopkins, C; Šurda, Pavol; Bast, F; Hettige, Roland; Walker, Abigail; Hellings, Peter

doi:10.4193/rhin17.027

Cited by 18 publications

(15 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When these criteria are not met, surgery is the treatment of choice to achieve disease control in CRSwNP. [63][64][65] However, surgery may have to be postponed in the current pandemic to save medical resources and to protect medical staff and patients from aerosolized virus particles (Recommendations of the ERS; https://www.europ eanrh inolo gicso ciety.org/?page_id=2143).…”

Section: Tre Atment Of Cr Swnpmentioning

confidence: 99%

Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic—An EAACI position paper

Klimek

Jutel

Bousquet

et al. 2021

Allergy

View full text Add to dashboard Cite

Background Chronic rhinosinusitis is regarded as a chronic airway disease. According to WHO recommendations, it may be a risk factor for COVID‐19 patients. In most CRSwNP cases, the inflammatory changes affecting the nasal and paranasal mucous membranes are type‐2 (T2) inflammation endotypes. Methods The current knowledge on COVID‐19 and on treatment options for CRS was analyzed by a literature search in Medline, Pubmed, international guidelines, the Cochrane Library and the Internet. Results Based on international literature, on current recommendations by WHO and other international organizations as well as on previous experience, a panel of experts from EAACI and ARIA provided recommendations for the treatment of CRS during the COVID‐19 pandemic. Conclusion Intranasal corticosteroids remain the standard treatment for CRS in patients with SARS‐CoV‐2 infection. Surgical treatments should be reduced to a minimum and surgery preserved for patients with local complications and for those with no other treatment options. Systemic corticosteroids should be avoided. Treatment with biologics can be continued with careful monitoring in noninfected patients and should be temporarily interrupted during the course of the COVID‐19 infection.

show abstract

Section: Tre Atment Of Cr Swnpmentioning

confidence: 99%

Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic—An EAACI position paper

Klimek

Jutel

Bousquet

et al. 2021

Allergy

View full text Add to dashboard Cite

show abstract

“…When this is insufficient, short courses of oral corticosteroids are used (usually 30‐60 mg for 14 days, sometimes reducing over time) . Sinus surgery is the treatment option for CRSwNP patients in cases failing medical treatment . Recently, also more attention has been paid to the concept of “treatable traits.” Treatable traits have been postulated as a management concept which complements the traditional diagnostic labels such as CRSwNP or CRSsNP, thereby focusing on therapy targeted to a patient's individual disease‐associated characteristics .…”

Section: Introductionmentioning

confidence: 99%

EUFOREA consensus on biologics for CRSwNP with or without asthma

Fokkens

Lund

Bachert

et al. 2019

Allergy

291

288

View full text Add to dashboard Cite

This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. AbstractNovel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of | 2313 FOKKENS Et al.

show abstract

“…The ability to identify patients at the highest risk for future AECRS and poor disease control would allow more personalized management through counseling patients about their expected CRS disease course or identification and avoidance of possible triggers (e.g., aeroallergens for the hypersensitive patient), closer monitoring of patients, or even consideration for more aggressive upfront treatment. 1,31 In this study, our goal was to study how appropriate medical management of CRS would impact CRS-related antibiotics use and CRS-related oral corticosteroids use as well as to identify factors that would be predictive of their future use. We found that appropriate medical management of CRS, consisting of intranasal saline and intranasal corticosteroids, was significantly associated with decreased CRS-related antibiotics use and CRSrelated oral corticosteroids use.…”

Section: Discussionmentioning

confidence: 99%

Appropriate medical management of chronic rhinosinusitis reduces use of antibiotics and oral corticosteroids

et al. 2019

View full text Add to dashboard Cite

Objectives/Hypothesis: Antibiotics and oral corticosteroids are used in the treatment of acute exacerbations of chronic rhinosinusitis (AECRS) and reflect poor disease control. We sought to characterize utilization of these systemic medications after appropriate medical management of chronic rhinosinusitis (CRS). Study Design: Prospective observational study. Methods: One hundred fifty patients undergoing medical management for CRS were studied. Data were collected at enrollment and follow-up 3 to 12 months later. All patients were asked to report the number of CRS-related antibiotics and oral corticosteroids used in the last 3 months. CRS symptom burden was measured using the 22-item Sino-Nasal Outcome Test (SNOT-22). Associations were sought between CRS-related antibiotics and oral corticosteroids use at follow-up compared to enrollment. Results: From enrollment to follow-up, the mean number of CRS-related antibiotics courses used decreased by 0.2 courses (95% confidence interval [CI]: 0.1-0.4, P = .012), and the mean number of CRS-related oral corticosteroid courses used also decreased by 0.2 courses (95% CI: 0.1-0.3, P = .029). The number of CRS-related antibiotics used at follow-up was associated with CRS-related antibiotic use at enrollment (adjusted rate ratio [RR] = 1.58, 95% CI: 1.17-2.13, P = .003). The number of CRS-related oral corticosteroids used at follow-up was associated with reported CRS-related oral corticosteroid use at enrollment (adjusted RR = 3.20, 95% CI: 1.69-6.07, P < .001). SNOT-22 results at enrollment were also not predictive of future systemic medication use. Conclusions: Appropriate medical management of CRS is associated with decreased use of oral antibiotics and corticosteroids. Previous utilization of antibiotics and oral corticosteroids for CRS is associated with future use of these medications.

show abstract

Prevention of chronic rhinosinusitis

Cited by 18 publications

References 98 publications

Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic—An EAACI position paper

Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic—An EAACI position paper

EUFOREA consensus on biologics for CRSwNP with or without asthma

Appropriate medical management of chronic rhinosinusitis reduces use of antibiotics and oral corticosteroids

Contact Info

Product

Resources

About